Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates

Transplantation

Volumn 70, Issue 6, 2000, Pages 969-975

  Ikonen, Tuija S ^a   Gummert, Jan F ^a   Hayase, Motoya ^b   Honda, Yasuhiro ^b   Hausen, Bernard ^a   Christians, Uwe ^c   Berry, Gerald J ^b   Yock, Paul G ^b   Morris, Randall E ^a,d  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; GRAFT REJECTION; HISTOPATHOLOGY; INTRAVASCULAR ULTRASOUND; MIXED LYMPHOCYTE REACTION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; VASCULAR DISEASE;

EID: 0034721484     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200009270-00015     Document Type: Article

References (35)

1. Identification of a new pharmacologic action for an old compound
2. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection
3. Use of rapamycin for the suppression of alloimmune reactions in vivo: Schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions
4. Rapamycin for immunosuppression in organ allografting
5. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat
6. Rapamycin: Personal algorithms for use based on 250 treated renal allograft recipients
7. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels
8. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement
9. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease
10. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506
11. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
12. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor
13. Rapamycin (sirolimus) inhibits vascular smooth muscle cell DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: Evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells
14. Multidimensional assessment of graft vascular disease (GVD) in aortic grafts by serial intravascular ultrasound in rhesus monkeys
15. Development of models of graft vascular disease in nonhuman primates: Evaluation of GVD by intravascular ultrasound in a new cynomolgus model with arterial allograft exchange
16. Sensitive and specific quantification of sirolimus rapamycin and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry
17. Graft vascular disease in the great vessels and vasa vasorum
18. Cardiac graft vascular disease. Nonselective involvement of large and small vessels
19. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production
20. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin
21. Probing immunosuppressant action with a nonnatural immunophilin ligand
22. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase
23. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase
24. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin
25. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model
26. Prevention and treatment of allograft rejection in vivo by rapamycin: Molecular and cellular mechanisms of action
27. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
28. The 59 kDa FK506-binding protein, a 90 kDa heat shock protein binding immunophilin FKBP59-HBI, is associated with the nucleus, the cytoskeleton and mitotic apparatus
29. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12
30. Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis
31. Sequential immunological targeting of chronic experimental arterial allograft
32. Rapamycin inhibits vascular smooth muscle cell migration
33. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts
34. Effects of cardiac allograft vasculopathy on myocardial blood flow, vasodilatory capacity, and coronary vasomotion
35. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related